Mark Allen Young, MD,MBA,FACP Physical Medicine & Rehabilitation - Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 5430 Campbell Blvd, Suite 205, White Marsh, MD 21162 Phone: 410-933-8800 Fax: 410-933-8900 |
News Archive
Patients with rheumatoid arthritis (RA) who initiated use of anti-tumor necrosis factor therapies were not at a higher risk of developing herpes zoster (shingles), compared with patients who initiated nonbiologic treatment regimens, according to research from the University of Alabama at Birmingham (UAB) and the Oregon Health and Science University. The findings appeared in the March 6, 2013, issue of the Journal of the American Medical Association (JAMA).
In the earliest days of brain development, the brain's first cells - neuroepithelial stem cells - divide continuously, producing a population of cells that eventually evolves into the various cells of the fully formed brain.
Fundraisers for GOP presidential hopeful Mitt Romney as well as for the Democratic Congressional Campaign Committee report significant tallies in the days since the Supreme Court's health law decision.
One of the top qualities that we look for in a long-term partner is kindness, according to new research by Swansea University.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that the U. S. Patent and Trademark Office has issued two patents covering the company's lead drug candidate and related compounds. One patent, US number 7,728,117, specifically covers GMI-1070, the Company's drug candidate now in clinical trials of patients with vaso-occlusive crisis of sickle cell disease. The second patent, US number 7,741,312, contains claims covering a family of molecules that includes and extends beyond GMI-1070.
› Verified 8 days ago